Tearsheet

AbbVie (ABBV)

Market Price (12/4/2025): $230.24 | Market Cap: $407.3 Bil
Sector: Health Care | Industry: Biotechnology

AbbVie (ABBV)

Market Price (12/4/2025): $230.24
Market Cap: $407.3 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 24%	Weak multi-year price returns 3Y Excs Rtn is -12%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 90x, P/EPrice/Earnings or Price/(Net Income) is 172x
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 33%, CFO LTM is 21 Bil, FCF LTM is 20 Bil
2	Attractive yield Dividend Yield is 2.8%
3	Low stock price volatility Vol 12M is 26%
4	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more.

0	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 24%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 33%, CFO LTM is 21 Bil, FCF LTM is 20 Bil
2	Attractive yield Dividend Yield is 2.8%
3	Low stock price volatility Vol 12M is 26%
4	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more.
5	Weak multi-year price returns 3Y Excs Rtn is -12%
6	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 90x, P/EPrice/Earnings or Price/(Net Income) is 172x

Valuation, Metrics & Events

	12/4/25	2024	2023	2022	2021
Share Price CYE	$230.24	$171.70	$144.45	$144.79	$116.76
Market Cap CYE ($ Bil)	407.3	303.7	255.4	256.4	207.0
Total Debt ($ Bil)	68.7	67.1	59.4	63.3	76.7
Total Cash ($ Bil)	5.7	5.6	12.8	9.2	9.8
Enterprise Value ($ Bil)	470.4	370.8	314.8	319.7	283.7
Valuation Ratios
P/S TTM	6.9	5.6	5.0	4.9	4.3
P/EBIT TTM	90.2	48.2	32.3	18.2	15.6
P/E TTM	171.5	73.5	56.3	24.2	20.8
Sector Ratios
P/S TTM (Sector)	2.3	1.9	2.2	3.8	3.5
P/EBIT TTM (Sector)	299.4	16.8	17.3	15.6	14.6
P/E TTM (Sector)	-69.7	95.4	21.3	23.7	18.6

	12/4/25	2024	2023
Share Price CYE	$230.24	$171.70	$144.45
Market Cap CYE ($ Bil)	407.3	303.7	255.4
Total Debt ($ Bil)	68.7	67.1	59.4
Total Cash ($ Bil)	5.7	5.6	12.8
Enterprise Value ($ Bil)	470.4	370.8	314.8
Valuation Ratios
P/S TTM	6.9	5.6	5.0
P/EBIT TTM	90.2	48.2	32.3
P/E TTM	171.5	73.5	56.3
Sector Ratios
P/S TTM (Sector)	2.3	1.9	2.2
P/EBIT TTM (Sector)	299.4	16.8	17.3
P/E TTM (Sector)	-69.7	95.4	21.3

	ABBV	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	59.6
Rev Chg Q	9.1%	7.1%
Rev Chg LTM	7.4%	6.1%
Rev Chg 3Y Avg	1.2%	5.5%
PROFITABILITY	FAIR
Op Inc LTM ($ Bil)	14.4
CFO LTM ($ Bil)	20.9
Net Inc LTM ($ Bil)	2.4
Op Mgn LTM	24.1%	18.8%
CFO/Rev LTM	35.0%	20.5%
Net Inc Mgn	4.0%	13.1%
VALUATION	MODERATE
P/S	6.9	3.2
P/CFO	19.7	15.8
P/FCF	20.8	20.5
P/E	171.7	23.5
STABILITY	GOOD
Debt/Equity	0.17	0.20
Cash/Assets	0.04	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Total Patents Globally	47143	11052025	Link
Active Patents	26893	11052025	Link
Compounds, Devices or Indications in Development	~90	9082025	Link
Programs in Mid and Late-Stage Development	~50	9082025	Link
Immunology Portfolio Global Net Revenues (Q3 2025)	$7.885 billion	9302025	Link
Neuroscience Portfolio Global Net Revenues (Q3 2025)	$2.841 billion	9302025	Link
Oncology Portfolio Global Net Revenues (Q3 2025)	$1.682 billion	9302025	Link
Aesthetics Portfolio Global Net Revenues (Q3 2025)	$1.193 billion	9302025	Link
Number of Employees	approximately 55,000	12312024	Link

Upcoming
1/16/2026	Dividend	Amount: $1.73 Payment On: 2/17/2026
1/30/2026	Earnings Release	Rev: - EPS: -

ABBV Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

The stock of AbbVie (ABBV) experienced significant movement between August 31, 2025, and December 5, 2025, driven by several key factors.

1. Strong Third-Quarter 2025 Financial Results: AbbVie reported better-than-expected third-quarter 2025 adjusted earnings per share (EPS) of $1.86, surpassing the consensus estimate of $1.77. The company's revenue also exceeded expectations, reaching $15.78 billion, a 9.1% increase year-over-year. This strong financial performance was largely attributed to robust sales of its newer immunology drugs, Skyrizi and Rinvoq.

2. Raised Full-Year 2025 EPS Guidance: Following the strong third-quarter results, AbbVie raised its adjusted diluted EPS guidance for the full year 2025 to a range of $10.61-$10.65, up from the previous guidance of $10.38-$10.58. This upward revision signaled confidence in the company's future performance and was a positive indicator for investors.

3. Dividend Increase: AbbVie's board of directors declared a 5.5% increase in the company's quarterly cash dividend, raising it from $1.64 per share to $1.73 per share. This commitment to returning cash to shareholders through a growing dividend, continuing a trend since the company's inception in 2013, likely bolstered investor confidence.

4. Positive Clinical Trial Data and Regulatory Submissions: AbbVie announced positive primary results from the pivotal Phase 3 ECLIPSE study, demonstrating the superiority of atogepant (AQUIPTA®) over placebo in achieving pain freedom for the acute treatment of migraine. The company also submitted an application to the European Medicines Agency for the expanded use of atogepant, potentially broadening treatment options in Europe. Furthermore, AbbVie presented new data at scientific conferences, showcasing advances in its oncology pipeline with investigational antibody-drug conjugates and treatments for various blood cancers. These developments highlight a strong and promising pipeline.

5. Analyst Sentiment and Price Target Revisions: Multiple investment analysts reiterated or upgraded their ratings for AbbVie, with several firms raising their price targets for the stock. The consensus among analysts was a "Moderate Buy" rating with an average target price of $241.85, suggesting potential upside. This positive analyst sentiment, reflecting confidence in the company's diversified product portfolio and pipeline strength, contributed to the stock's upward movement.

Show less

Stock Movement Drivers

Fundamental Drivers

The 8.3% change in ABBV stock from 9/4/2025 to 12/4/2025 was primarily driven by a 70.7% change in the company's P/E Multiple.

	9042025	12042025	Change
Stock Price ($)	211.48	229.00	8.29%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	58328.00	59644.00	2.26%
Net Income Margin (%)	6.45%	4.00%	-37.94%
P/E Multiple	99.36	169.64	70.73%
Shares Outstanding (Mil)	1768.00	1769.00	-0.06%
Cumulative Contribution			8.29%

LTM = Last Twelve Months as of date shown

Market Drivers

9/4/2025 to 12/4/2025

	Return	Correlation
ABBV	8.1%
Market (SPY)	5.4%	4.3%
Sector (XLV)	12.0%	63.6%

Fundamental Drivers

The 24.1% change in ABBV stock from 6/5/2025 to 12/4/2025 was primarily driven by a 118.1% change in the company's P/E Multiple.

	6052025	12042025	Change
Stock Price ($)	184.53	229.00	24.10%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	57367.00	59644.00	3.97%
Net Income Margin (%)	7.31%	4.00%	-45.25%
P/E Multiple	77.77	169.64	118.12%
Shares Outstanding (Mil)	1768.00	1769.00	-0.06%
Cumulative Contribution			24.10%

LTM = Last Twelve Months as of date shown

Market Drivers

6/5/2025 to 12/4/2025

	Return	Correlation
ABBV	23.9%
Market (SPY)	15.7%	4.4%
Sector (XLV)	16.2%	60.9%

Fundamental Drivers

The 34.3% change in ABBV stock from 12/4/2024 to 12/4/2025 was primarily driven by a 188.1% change in the company's P/E Multiple.

	12042024	12042025	Change
Stock Price ($)	170.50	229.00	34.31%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	55533.00	59644.00	7.40%
Net Income Margin (%)	9.22%	4.00%	-56.59%
P/E Multiple	58.89	169.64	188.08%
Shares Outstanding (Mil)	1769.00	1769.00	0.00%
Cumulative Contribution			34.31%

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2024 to 12/4/2025

	Return	Correlation
ABBV	34.1%
Market (SPY)	13.7%	30.9%
Sector (XLV)	6.3%	68.0%

Fundamental Drivers

The 55.9% change in ABBV stock from 12/5/2022 to 12/4/2025 was primarily driven by a 774.3% change in the company's P/E Multiple.

	12052022	12042025	Change
Stock Price ($)	146.88	229.00	55.91%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	57819.00	59644.00	3.16%
Net Income Margin (%)	23.19%	4.00%	-82.73%
P/E Multiple	19.40	169.64	774.33%
Shares Outstanding (Mil)	1771.00	1769.00	0.11%
Cumulative Contribution			55.91%

LTM = Last Twelve Months as of date shown

Market Drivers

12/5/2023 to 12/4/2025

	Return	Correlation
ABBV	69.7%
Market (SPY)	53.3%	23.1%
Sector (XLV)	20.1%	59.6%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ABBV Return	28%	32%	24%	-0%	19%	33%	231%
Peers Return	3%	20%	29%	9%	11%	22%	138%
S&P 500 Return	16%	27%	-19%	24%	23%	17%	112%
Monthly Win Rates [3]
ABBV Win Rate	58%	75%	67%	50%	67%	60%
Peers Win Rate	50%	47%	62%	45%	55%	54%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
ABBV Max Drawdown	-26%	-3%	-2%	-16%	0%	-4%
Peers Max Drawdown	-19%	-7%	-8%	-16%	-12%	-14%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, MRK, AMGN, GILD, BMY. See ABBV Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/4/2025 (YTD)

How Low Can It Go

Unique Key	Event	ABBV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-23.3%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	30.4%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	495 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-34.0%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	51.6%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	99 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-48.9%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	95.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	847 days	120 days

Compare to LLY, MRK, AMGN, GILD, BMY

In The Past

AbbVie's stock fell -23.3% during the 2022 Inflation Shock from a high on 4/8/2022. A -23.3% loss requires a 30.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AI Generated Analysis | Feedback

Here are 1-3 brief analogies for AbbVie:

A major pharmaceutical company like Pfizer, specializing in immunology, oncology, and neuroscience.
Amgen, but with a broader portfolio of blockbuster drugs spanning immunology, oncology, and aesthetics.
The dedicated research and drug development arm of a company like Abbott Laboratories, but operating as an independent entity.

AI Generated Analysis | Feedback

Humira (adalimumab): A blockbuster biologic drug for various autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease.
Skyrizi (risankizumab): An interleukin-23 inhibitor used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Rinvoq (upadacitinib): A JAK inhibitor approved for several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis.
Botox (onabotulinumtoxinA): A neurotoxin widely used for both cosmetic purposes (reducing wrinkles) and therapeutic indications such as chronic migraine and muscle spasticity.
Venclexta/Venclyxto (venetoclax): An oral medication for certain types of leukemia and lymphoma, specifically chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Imbruvica (ibrutinib): A Bruton's tyrosine kinase (BTK) inhibitor used to treat various B-cell cancers, including chronic lymphocytic leukemia and mantle cell lymphoma.

AI Generated Analysis | Feedback

AbbVie (ABBV) primarily sells its pharmaceutical products to other companies, specifically major pharmaceutical wholesale distributors.

Its major customers in the United States, based on recent financial disclosures, are the three largest pharmaceutical wholesale distributors. These companies purchase a significant portion of AbbVie's products for distribution to pharmacies, hospitals, and other healthcare providers:

AmerisourceBergen Corporation (Symbol: ABC)
Cardinal Health, Inc. (Symbol: CAH)
McKesson Corporation (Symbol: MCK)

These three distributors collectively account for a substantial majority of AbbVie's gross revenues in the United States.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

The emergence of next-generation neurotoxins, such as Daxxify (daxibotulinumtoxinA) by Revance Therapeutics, approved in 2022, offers a longer duration of effect compared to traditional botulinum toxins like AbbVie's Botox. This directly challenges Botox's market dominance by providing a differentiated product that may reduce the frequency of treatments, representing a clear new competitive pressure.
Increased competition in the immunology market from recently approved and highly efficacious biologics and small molecules. Examples include Eli Lilly's Omvoh (mirikizumab) for ulcerative colitis, which received approvals in late 2023 and early 2024 in key markets, and Bristol Myers Squibb's Sotyktu (deucravacitinib) for psoriasis. These new entrants directly compete with AbbVie's key immunology assets like Skyrizi and Rinvoq, intensifying the fight for market share.

AI Generated Analysis | Feedback

AbbVie (ABBV) operates in several significant addressable markets for its main products and services, primarily focusing on immunology, oncology, and aesthetics.

Humira (adalimumab): The global market size for Humira was estimated at approximately USD 10.34 billion in 2024. This market is projected to decline to about USD 4.11 billion by 2030, primarily due to the increasing availability of biosimilars following patent expirations. North America holds a leading position in the Humira market, accounting for 85.7% of the global share in 2024, with the U.S. dominating within North America.
Skyrizi (risankizumab): Global sales for Skyrizi are projected to reach USD 17.1 billion in 2025. In 2024, its sales were approximately USD 11.7 billion. Combined with Rinvoq, AbbVie anticipates their immunology portfolio will generate over USD 31 billion in sales by 2027. North America was the largest region for Skyrizi in 2024.
Rinvoq (upadacitinib): Global sales for Rinvoq are projected to be USD 8 billion in 2025. Its sales in 2024 were around USD 6 billion. The combined sales of Rinvoq and Skyrizi are expected to exceed USD 31 billion by 2027. The market size for Giant Cell Arteritis (GCA), one of its indications, is estimated to grow from USD 960 million in the 7 major markets (7MM) in 2023.
Imbruvica (ibrutinib): The global Imbruvica market size was approximately USD 9.6982 billion in 2024. It is expected to expand to USD 44.462 billion by 2031, with a compound annual growth rate (CAGR) of 24.30% from 2024 to 2031. North America accounted for over 40% of the global revenue for Imbruvica in 2024.
Botox (Botulinum Toxin): The global botulinum toxin market, which includes Botox, was valued at USD 9.77 billion in 2025 and is forecast to reach USD 15.10 billion by 2030. The medical Botox market specifically had a size of USD 5.4122 million in 2024 and is projected to reach USD 10.2158 billion by 2031, growing at a CAGR of 9.50% from 2024 to 2031. North America held the highest market share in the botulinum toxin market in 2024.
Venclexta/Venclyxto (venetoclax): The global venetoclax market size was valued at USD 1.22 billion in 2024 and is estimated to reach USD 2.43 billion by 2033, growing at a CAGR of 12.92% from 2025 to 2033. North America dominates this global market.

AI Generated Analysis | Feedback

AbbVie (ABBV) is anticipated to drive future revenue growth over the next two to three years through several key strategies:

Continued Growth of Immunology Blockbusters: The strong performance of immunology drugs SKYRIZI and RINVOQ is a significant growth driver. These products are consistently exceeding sales expectations, with projections for combined sales to surpass $15 billion by 2027 and over $31 billion by 2027 due to expanded indications and global market penetration.
Expansion and Performance of the Neuroscience Portfolio: AbbVie's neuroscience portfolio, featuring products such as Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta, is demonstrating robust double-digit revenue growth. Strategic acquisitions, including Cerevel Therapeutics, are expected to further bolster this segment and address unmet needs in neurodegenerative diseases.
Advancements in the Oncology Pipeline: The oncology portfolio, with products like Venclexta, is also contributing to growth. The acquisition of ImmunoGen is poised to catalyze further expansion and innovation within AbbVie's oncology offerings.
Strategic Investments in R&D and External Innovation: AbbVie is actively investing in research and development and pursuing strategic acquisitions to strengthen its pipeline across core therapeutic areas like immunology, oncology, neuroscience, and new growth areas such as obesity and mood disorders. Recent deals, including the acquisition of Gilgamesh Pharmaceuticals and Capstan Therapeutics, aim to expand the psychiatry and immunology pipelines, respectively.

AI Generated Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years) for AbbVie (ABBV)

Share Repurchases

AbbVie repurchased 10 million shares for $1.6 billion in 2023, 8 million shares for $1.1 billion in 2022, and 7 million shares for $1.3 billion in 2024.
On February 16, 2023, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization.
The remaining stock repurchase authorization was $3.5 billion as of December 31, 2024.

Share Issuance

AbbVie's shares outstanding were 1.773 billion in 2024, showing a 0% decline from 2023.
Shares outstanding were 1.773 billion in 2023, a 0.28% decline from 2022.
The company issued and redeemed $7.7 billion of commercial paper during 2024.

Outbound Investments

AbbVie acquired ImmunoGen for $10.1 billion in February 2024 (agreement in November 2023) to accelerate its entry into the ovarian cancer treatment market.
The company acquired Cerevel Therapeutics for $8.7 billion in August 2024 (agreement in December 2023) to significantly strengthen its neuroscience pipeline.
AbbVie's deal activity surged in 2024 with 17 deals, primarily licensing and R&D collaborations to enhance its pipeline, including a partnership with FutureGen Biopharmaceutical for up to $1.7 billion for Inflammatory Bowel Disease treatment.

Capital Expenditures

AbbVie's capital expenditures averaged $806.2 million annually from 2020 to 2024, with $974 million in 2024 and a peak of $1.044 billion in the latest twelve months (as of June 2025).
The company plans to invest over $10 billion in U.S. manufacturing during the next decade to support volume growth and expand into new therapeutic areas like obesity.
A $195 million investment in its North Chicago manufacturing plant to expand domestic active pharmaceutical ingredient (API) production is set to begin construction in fall 2025 and be fully operational by 2027.

Better Bets than AbbVie (ABBV)

	ABBV	Better Performance than ABBV
Metric	Value	INDUSTRY: Biotechnology
Rev Chg LTM	7.4%	ALNY (53.2%), INSM (30.3%), UTHR (13.5%), AMGN (10.6%), VRTX (10.3%)
Rev Chg 3Y Avg	1.2%	ALNY (51.4%), AMGN (11.2%), VRTX (10.5%), GILD (2.3%), REGN (1.4%)
Op Mgn LTM	24.1%	UTHR (48.7%), GILD (38.3%), REGN (26.7%), BIIB (24.8%), AMGN (24.1%)
CFO/Rev LTM	35.0%	RPRX (102.4%), UTHR (49.7%), HALO (49.2%), AMGN (36.5%), REGN (35.6%)
FCF/Rev LTM	33.0%	RPRX (102.4%), KRYS (51.6%), HALO (48.5%), CPRX (40.6%), UTHR (35.7%)
Total Yield	3.4%	GILD (8.8%), REGN (8.3%), AMGN (7.9%), BIIB (7.8%), VRTX (3.7%)
P/S	6.9	BIIB (2.0), REGN (4.1), AMGN (4.2), GILD (4.7), UTHR (5.9)
P/Op Inc	28.5	BIIB (8.2), UTHR (12.1), GILD (12.4), REGN (15.3), AMGN (17.5)

	ABBV	Better Performance than ABBV
Metric	Value	SECTOR: Health Care
Rev Chg LTM	7.4%	LLY (36.8%), ISRG (22.2%), BSX (21.6%), AMGN (10.6%), UNH (10.5%)
Rev Chg 3Y Avg	1.2%	LLY (23.4%), ISRG (16.3%), UNH (11.4%), JNJ (6.1%), MRK (2.9%)
Op Mgn LTM	24.1%	LLY (43.0%), MRK (34.9%), ISRG (29.3%), JNJ (26.2%), AMGN (24.1%)
CFO/Rev LTM	35.0%	UTHR (49.7%), VEEV (45.5%), AMGN (36.5%), RMD (35.8%), REGN (35.6%)
FCF/Rev LTM	33.0%	RPRX (102.4%), DOCS (50.2%), VEEV (45.5%), UTHR (35.7%), RMD (33.4%)
Total Yield	3.4%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABT (7.7%), TMO (3.6%)
P/S	6.9	UNH (0.7), MRK (3.3), TMO (4.2), JNJ (4.8), ABT (5.3)
P/Op Inc	28.5	MRK (9.4), UNH (11.9), AMGN (17.5), JNJ (18.5), TMO (22.8)

	ABBV	Better Performance than ABBV
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	7.4%	NVDA (71.6%), AVGO (28.0%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%)
Rev Chg 3Y Avg	1.2%	NVDA (92.0%), MSFT (13.2%), AMZN (11.3%), GOOGL (11.0%), AAPL (1.8%)
Op Mgn LTM	24.1%	NVDA (58.1%), MSFT (46.3%), AVGO (39.0%), GOOGL (32.2%), AAPL (31.9%)
CFO/Rev LTM	35.0%	META (56.8%), MSFT (50.0%), NVDA (46.6%), AVGO (42.4%), GOOGL (39.3%)
FCF/Rev LTM	33.0%	V (53.9%), MA (52.5%), PLTR (46.0%), NVDA (43.6%), AVGO (41.6%)
Total Yield	3.4%	JPM (6.7%), BRK-B (6.2%), GOOGL (4.6%), WMT (3.6%), META (3.5%)
P/S	6.9	WMT (1.1), XOM (1.4), BRK-B (2.7), AMZN (3.5), JPM (4.9)
P/Op Inc	28.5	XOM (12.4), META (22.6), GOOGL (23.7), WMT (26.9), MSFT (28.3)

		Best Bets In Health Care Sector
	ABBV	RPRX	HALO	DOCS	UTHR	CPRX	HRMY	LGND	ISRG	GMED	MD
What You Pay
P/E	171.5	19.9	14.4	54.3	14.4	11.1	8.5	71.4	58.1	18.2	8.7
P/EBIT	90.2	9.6	11.3	55.6	10.9	9.3	6.5	51.9	56.6	17.8	5.9
What You Get
Rev Chg Q	9.1%	7.9%	22.1%	23.2%	6.8%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%
Rev Chg LTM	7.4%	3.7%	31.2%	20.2%	13.5%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%
Rev Chg 3Y Avg	1.2%	1.5%	29.0%	17.4%	19.0%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%
FCF/Rev 3Y Avg	35.3%	115.2%	45.0%	42.7%	34.3%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	With AbbVie Stock Surging, Have You Considered The Downside?	Return
2	Should You Buy AbbVie Stock?	Buy or Fear
3	ABBV Leaps 5.5% In One Day: Does It Lead the Pack?
4	ABBV's One-Day Rally Offers a Chance to Reevaluate UTHR	Counter-Intuitive Comparisons
5	AbbVie vs Zoetis: Which Is A Better Investment?	Counter-Intuitive Comparisons
6	AbbVie vs Royalty Pharma: Which Is A Better Investment?	Counter-Intuitive Comparisons
7	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From GOOGL, META
8	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From UNH, HCA
9	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From UTHR, NBIX
10	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From INCY, UTHR, NBIX, BMRN	Actionable
11	ARTICLES
12	How Will AbbVie Stock React To Its Upcoming Earnings?		October 30th, 2025
13	ABBV Up 5.5% in One Day, Should You Buy The Stock?		October 2nd, 2025
14	ABBV Surges 5.5% In A Single Day: Where Does It Rank Among Competitors?		October 2nd, 2025
15	Big Move for ABBV, but Do UTHR’s Margins and Growth Give It the Edge?		October 2nd, 2025
16	Large Cap Stocks Trading At 52-Week High		September 11th, 2025

	Title
0	DASHBOARDS
1	With AbbVie Stock Surging, Have You Considered The Downside?
2	Should You Buy AbbVie Stock?
3	ABBV Leaps 5.5% In One Day: Does It Lead the Pack?
4	ABBV's One-Day Rally Offers a Chance to Reevaluate UTHR
5	AbbVie vs Zoetis: Which Is A Better Investment?
6	AbbVie vs Royalty Pharma: Which Is A Better Investment?
7	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From GOOGL, META
8	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From UNH, HCA
9	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From UTHR, NBIX
10	Better Bet Than ABBV Stock: Pay Less Than AbbVie To Get More From INCY, UTHR, NBIX, BMRN
11	ARTICLES
12	How Will AbbVie Stock React To Its Upcoming Earnings?
13	ABBV Up 5.5% in One Day, Should You Buy The Stock?
14	ABBV Surges 5.5% In A Single Day: Where Does It Rank Among Competitors?
15	Big Move for ABBV, but Do UTHR’s Margins and Growth Give It the Edge?
16	Large Cap Stocks Trading At 52-Week High

Trade Ideas

Select past ideas related to ABBV. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%
ABBV_4302022_Quality_Momentum_RoomToRun_10%	04302022	ABBV	AbbVie	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	2.5%	6.9%	-7.8%
ABBV_10312018_Dip_Buyer_FCFYield	10312018	ABBV	AbbVie	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	3.9%	8.0%	-15.8%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	10.0%	10.0%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.7%	-7.7%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.9%	6.9%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	11.5%	11.5%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	8.9%	8.9%	-5.1%
ABBV_4302022_Quality_Momentum_RoomToRun_10%	04302022	ABBV	AbbVie	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	2.5%	6.9%	-7.8%
ABBV_10312018_Dip_Buyer_FCFYield	10312018	ABBV	AbbVie	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	3.9%	8.0%	-15.8%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
LXP	LXP Industrial Trust	2.8	406.1%	25.7%
OLMA	Olema Pharmaceuticals	2.4	237.1%	374.1%
COGT	Cogent Biosciences	5.4	178.2%	404.0%
CDTX	Cidara Therapeutics	5.9	119.6%	720.3%
SGML	Sigma Lithium	1.1	113.2%	-11.1%
IRWD	Ironwood Pharmaceuticals	0.6	99.5%	-15.8%
ALMS	Alumis	0.6	82.4%	5.6%
NPCE	NeuroPace	0.6	80.5%	51.7%
BW	Babcock & Wilcox Enterprises	0.7	80.5%	311.6%
CBLL	CeriBell	0.7	75.4%	-26.0%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
CCOI	Cogent Communications	0.9	-53.0%	-74.0%
UP	Wheels Up Experience	0.5	-48.0%	-60.0%
TLRY	Tilray Brands	7.7	-41.8%	-45.7%
AMSC	American Superconductor	1.4	-41.4%	34.0%
CTEV	Claritev	0.6	-41.2%
BTDR	Bitdeer Technologies	2.5	-40.7%	-41.6%
FRMI	Fermi	11.1	-40.2%
JANX	Janux Therapeutics	1.0	-39.3%	-69.4%
ARDT	Ardent Health	1.2	-39.1%	-48.1%
SMR	NuScale Power	3.4	-35.9%	27.4%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
USAR	USA Rare Earth	1.8	24.7%	58557.7%
PATH	UiPath	9.9	24.4%	45.4%
ASTS	AST SpaceMobile	17.6	18.2%	244.3%
FLNC	Fluence Energy	3.1	17.6%	47.0%
SAIC	Science Applications International	4.8	16.3%	-7.7%
AEVA	Aeva Technologies	0.9	16.0%	234.3%
AXGN	Axogen	1.5	16.0%	99.4%
SANA	Sana Biotechnology	1.3	15.9%	217.8%
OKLO	Oklo	15.6	15.6%	425.9%
RGTI	Rigetti Computing	9.0	15.4%	97.0%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
HOV	Hovnanian Enterprises	0.7	-22.5%	-22.4%
SYM	Symbotic	6.6	-17.4%	155.1%
BBW	Build-A-Bear Workshop	0.6	-15.5%	7.1%
DJCO	Daily Journal	0.6	-11.9%	-22.5%
PVH	PVH	3.7	-11.9%	-26.9%
SNOW	Snowflake	78.7	-11.4%	52.0%
QURE	uniQure	1.2	-10.8%	28.8%
MBX	MBX Biosciences	1.0	-10.0%	65.7%
WLY	John Wiley & Sons	1.8	-8.6%	-18.7%
LUMN	Lumen Technologies	8.7	-8.3%	65.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	7.7	601.0%	-45.7%
HPP	Hudson Pacific Properties	6.1	591.8%	-36.1%
AEVA	Aeva Technologies	0.9	50.8%	234.3%
MPLT	MapLight Therapeutics	0.8	41.2%
USAR	USA Rare Earth	1.8	40.6%	58557.7%
PATH	UiPath	9.9	36.0%	45.4%
EVEX	Eve	1.6	34.4%	-7.4%
TMC	TMC The Metals	2.9	33.8%	596.4%
TE	T1 Energy	0.8	33.1%
INDI	Indie Semiconductor	0.9	32.1%	13.8%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.0	-52.7%	-69.4%
CTEV	Claritev	0.6	-32.7%
SYM	Symbotic	6.6	-30.7%	155.1%
FULC	Fulcrum Therapeutics	0.5	-22.6%	86.4%
HOV	Hovnanian Enterprises	0.7	-22.0%	-22.4%
VTYX	Ventyx Biosciences	0.6	-19.9%	265.3%
SIG	Signet Jewelers	3.5	-17.8%	7.2%
CMCL	Caledonia Mining	0.5	-17.8%	175.7%
QURE	uniQure	1.2	-17.7%	28.8%
URGN	UroGen Pharma	1.2	-17.5%	128.0%

Peer Comparisons for AbbVie

Peers to compare with:

Financials

	ABBV	LLY	MRK	AMGN	GILD	BMY	Median
Name	AbbVie	Eli Lilly	Merck	Amgen	Gilead S.	Bristol-.
Mkt Price	229.00	1,012.30	101.02	341.52	123.51	52.06	176.26
Mkt Cap	405.1	908.9	252.0	183.7	153.5	106.0	217.9
Rev LTM	59,644	53,258	64,235	35,971	29,086	48,034	50,646
Op Inc LTM	14,366	22,882	22,391	8,671	11,151	11,420	12,893
FCF LTM	19,684	-50	13,049	11,539	9,162	15,302	12,294
FCF 3Y Avg	20,012	-156	13,685	9,067	8,815	13,598	11,332
CFO LTM	20,860	10,938	17,065	13,126	9,667	16,621	14,874
CFO 3Y Avg	20,962	7,230	17,506	10,322	9,364	14,846	12,584

Growth & Margins

	ABBV	LLY	MRK	AMGN	GILD	BMY	Median
Name	AbbVie	Eli Lilly	Merck	Amgen	Gilead S.	Bristol-.
Rev Chg LTM	7.4%	36.8%	1.7%	10.6%	2.8%	1.3%	5.1%
Rev Chg 3Y Avg	1.2%	23.4%	2.9%	11.2%	2.3%	1.0%	2.6%
Rev Chg Q	9.1%	37.6%	3.7%	12.4%	3.0%	2.8%	6.4%
QoQ Delta Rev Chg LTM	2.3%	8.7%	1.0%	3.0%	0.8%	0.7%	1.6%
Op Mgn LTM	24.1%	43.0%	34.9%	24.1%	38.3%	23.8%	29.5%
Op Mgn 3Y Avg	27.0%	35.6%	23.7%	25.4%	39.2%	19.0%	26.2%
QoQ Delta Op Mgn LTM	0.6%	1.8%	3.7%	0.6%	0.9%	2.9%	1.4%
CFO/Rev LTM	35.0%	20.5%	26.6%	36.5%	33.2%	34.6%	33.9%
CFO/Rev 3Y Avg	37.0%	17.8%	28.2%	32.7%	33.1%	31.7%	32.2%
FCF/Rev LTM	33.0%	-0.1%	20.3%	32.1%	31.5%	31.9%	31.7%
FCF/Rev 3Y Avg	35.3%	0.5%	22.0%	28.8%	31.2%	29.0%	28.9%

Valuation

	ABBV	LLY	MRK	AMGN	GILD	BMY	Median
Name	AbbVie	Eli Lilly	Merck	Amgen	Gilead S.	Bristol-.
Mkt Cap	405.1	908.9	252.0	183.7	153.5	106.0	217.9
P/S	6.9	12.8	3.3	4.2	4.8	1.9	4.5
P/EBIT	90.3	38.5	9.1	13.7	12.7	9.2	13.2
P/E	171.7	49.5	11.0	21.8	17.1	15.2	19.4
P/CFO	19.7	62.5	12.3	11.6	14.4	5.5	13.3
Total Yield	3.4%	2.7%	13.0%	7.9%	8.8%	12.0%	8.4%
Dividend Yield	2.8%	0.7%	3.9%	3.3%	2.9%	5.4%	3.1%
FCF Yield 3Y Avg	6.2%	0.1%	5.5%	5.9%	8.0%	13.2%	6.1%
D/E	0.2	0.1	0.2	0.4	0.2	0.6	0.2
Net D/E	0.2	0.1	0.1	0.3	0.1	0.4	0.1

Returns

	ABBV	LLY	MRK	AMGN	GILD	BMY	Median
Name	AbbVie	Eli Lilly	Merck	Amgen	Gilead S.	Bristol-.
1M Rtn	6.1%	11.8%	20.5%	15.9%	0.4%	14.2%	13.0%
3M Rtn	8.3%	36.5%	21.4%	22.8%	10.3%	13.0%	17.2%
6M Rtn	24.1%	32.7%	32.7%	20.8%	13.4%	11.8%	22.4%
12M Rtn	34.3%	22.9%	3.3%	26.7%	38.9%	-6.4%	24.8%
3Y Rtn	55.9%	180.7%	0.4%	31.9%	56.3%	-26.3%	43.9%
1M Excs Rtn	4.8%	10.5%	19.2%	14.7%	-0.9%	12.9%	11.7%
3M Excs Rtn	2.7%	33.6%	14.6%	15.4%	2.3%	6.1%	10.4%
6M Excs Rtn	8.6%	17.3%	17.3%	5.3%	-2.2%	-3.7%	6.9%
12M Excs Rtn	17.0%	14.1%	-9.3%	13.4%	21.8%	-22.3%	13.8%
3Y Excs Rtn	-11.8%	111.7%	-71.9%	-40.3%	-13.5%	-98.2%	-26.9%

Comparison Analyses

	Title
0	AbbVie vs. Bristol Myers Squibb: With Return Forecast Of 47%, Bristol Myers Squibb Is A Better Bet
1	AbbVie vs. Merck: With Return Forecast Of 10%, AbbVie Is A Better Bet
2	AbbVie vs. Eli Lilly and Company: With Return Forecast Of 10%, AbbVie Is A Better Bet
3	AbbVie vs. Cisco: With Return Forecast Of 14%, AbbVie Is A Better Bet
4	AbbVie vs. Deere: With Return Forecast Of 14%, AbbVie Is A Better Bet
5	AbbVie vs. Comcast: With Return Forecast Of 28%, Comcast Is A Better Bet
6	AbbVie vs. Costco: With Return Forecast Of 13%, AbbVie Is A Better Bet
7	AbbVie vs. Oracle: With Return Forecast Of 13%, AbbVie Is A Better Bet
8	AbbVie vs. Advanced Micro Devices: With Return Forecast Of 29%, Advanced Micro Devices Is A Better Bet
9	AbbVie vs. International Business Machines: With Return Forecast Of 17%, AbbVie Is A Better Bet

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/4/2025	2/14/2025	2/20/2024	2/17/2023	2/18/2022	2/19/2021	2/21/2020
Key Financials
Total Revenue	59,644	56,334	54,318	58,054	56,197	45,804	33,266
EBITDA	12,795	14,910	17,172	24,174	23,933	12,323	12,227
Operating Income	14,366	11,894	13,535	18,814	17,924	11,363	12,983
Net Income	2,388	4,278	4,863	11,836	11,542	4,616	7,882
EPS	1.33	2.40	2.73	6.65	6.48	2.73	5.30
Growth Rates
Total Revenue Growth	7.4%	3.7%	-6.4%	3.3%	22.7%	37.7%	1.6%
EBITDA Growth	-29.8%	-13.2%	-29.0%	1.0%	94.2%	0.8%	47.1%
Operating Income Growth	-6.0%	-12.1%	-28.1%	5.0%	57.7%	-12.5%	103.4%
Net Income Growth	-53.4%	-12.0%	-58.9%	2.5%	150.0%	-41.4%	38.6%
Margins
EBITDA Margin	21.5%	26.5%	31.6%	41.6%	42.6%	26.9%	36.8%
Operating Income Margin	24.1%	21.1%	24.9%	32.4%	31.9%	24.8%	39.0%
Net Income Margin	4.0%	7.6%	9.0%	20.4%	20.5%	10.1%	23.7%
Cash & Debt
Total Cash	5,671	5,555	12,816	9,229	9,830	8,479	39,924
Total Debt	68,743	67,144	59,385	63,271	76,684	86,056	66,728
Net Debt / (Cash)	63,072	61,589	46,569	54,042	66,854	77,577	26,804
Cash Flows
Net Cash from Operations	20,860	18,806	22,839	24,943	22,777	17,588	13,324
Free Cash from Operations	19,684	17,832	22,062	24,248	21,990	16,790	12,772
Returns to Shareholders
Dividends	11,498	11,025	10,539	10,043	9,261	7,716	6,366
Share Repurchases	1,335	1,708	1,972	1,487	934	978	629

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/4/2025	8/4/2025	5/9/2025	2/14/2025	11/4/2024	8/7/2024	5/3/2024	2/20/2024	11/6/2023	8/7/2023	5/5/2023	2/17/2023
Key Financials Quarterly
Total Revenue	15,776	15,423	13,343	15,102	14,460	14,462	12,310	14,301	13,927	13,865	12,225	15,121
Ebitda	3,516	4,344	4,400	535	4,883	5,003	4,489	3,852	4,743	5,422	3,155	5,688
Operating Income	4,584	5,717	3,981	84	3,913	4,935	2,962	3,477	2,347	4,793	2,918	6,199
Net Income	186	938	1,286	-22	1,561	1,370	1,369	822	1,778	2,024	239	2,473
EPS	0.10	0.52	0.72	-0.01	0.88	0.77	0.77	0.47	1.00	1.14	0.13	1.40
Key Financials TTM
Total Revenue TTM	59,644	58,328	57,367	56,334	55,533	55,000	54,403	54,318	55,138	56,023	56,741	58,054
Ebitda TTM	12,795	14,162	14,821	14,910	18,227	18,087	18,506	17,172	19,008	21,430	19,799	24,174
Operating Income TTM	14,366	13,695	12,913	11,894	15,287	13,721	13,579	13,535	16,257	18,513	17,015	18,814
Net Income TTM	2,388	3,763	4,195	4,278	5,122	5,339	5,993	4,863	6,514	8,685	7,585	11,836
Growth Rates Quarterly
Total Revenue Growth	9.1%	6.6%	8.4%	5.6%	3.8%	4.3%	0.7%	-5.4%	-6.0%	-4.9%	-9.7%	1.6%
EBITDA Growth	-28.0%	-13.2%	-2.0%	-86.1%	3.0%	-7.7%	42.3%	-32.3%	-33.8%	43.0%	-58.1%	-16.7%
Operating Income Growth	17.1%	15.8%	34.4%	-97.6%	66.7%	3.0%	1.5%	-43.9%	-49.0%	45.5%	-38.1%	22.2%
Net Income Growth	-88.1%	-31.5%	-6.1%	-102.7%	-12.2%	-32.3%	472.8%	-66.8%	-55.0%	119.0%	-94.7%	-38.8%
Margins Quarterly
EBITDA Margin	22.3%	28.2%	33.0%	3.5%	33.8%	34.6%	36.5%	26.9%	34.1%	39.1%	25.8%	37.6%
Operating Income Margin	29.1%	37.1%	29.8%	0.6%	27.1%	34.1%	24.1%	24.3%	16.9%	34.6%	23.9%	41.0%
Net Income Margin	1.2%	6.1%	9.6%	-0.1%	10.8%	9.5%	11.1%	5.7%	12.8%	14.6%	2.0%	16.4%
Cash & Debt
Total Cash	5,671	6,467	5,176	5,555	7,285	13,157	18,069	12,816	13,290	8,766	6,722	9,229
Total Debt	68,743	70,481	69,889	67,144	71,079	70,634	74,001	59,385	60,746	61,015	62,093	63,271
Net Debt / (Cash)	63,072	64,014	64,713	61,589	63,794	57,477	55,932	46,569	47,456	52,249	55,371	54,042
Cash Flows Quarterly
FCF from Operations	7,024	5,153	1,635	7,048	5,447	2,271	4,040	4,753	7,574	6,319	4,193	7,428
Cash Flows TTM
FCF from Operations TTM	20,860	19,283	16,401	18,806	16,511	18,638	22,686	22,839	25,514	25,542	24,228	24,943
Returns to Shareholders Quarterly
Dividends	2,911	2,910	2,925	2,752	2,751	2,750	2,772	2,626	2,627	2,625	2,661	2,506
Share Repurchases	4	12	961	358	17	9	1,324	3	4	10	1,955	4
Return on Invested Capital (ROIC) Quarterly
ROIC	7.4%	20.9%	18.6%	0.0%	17.5%	21.0%	15.8%	18.4%	16.4%	26.2%	9.9%	33.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	21.9%	20.7%	19.4%	18.4%	16.3%	17.3%	18.5%	20.5%	25.4%	27.1%	24.0%	26.7%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Humira	14,404	21,237	20,694	19,832	19,169
Skyrizi	7,763	5,165	2,939	1,590	355
Rinvoq	3,969	2,522	1,651	731	47
Imbruvica	3,596	4,568	5,408	5,314	4,674
All other	3,035	4,137	5,019	2,923	2,068
Botox Therapeutic	2,991	2,719	2,451	1,387
Vraylar	2,759	2,038	1,728	951
Botox Cosmetic	2,682	2,615	2,232	1,112
Venclexta	2,288	2,009	1,820	1,337	792
Mavyret	1,430	1,541	1,710	1,830	2,893
Juvederm Collection	1,378	1,428	1,535	718
Creon	1,268	1,278	1,191	1,114	1,041
Other Aesthetics	1,234	1,290	1,466	760
Linzess/Constella	1,108	1,035	1,038	667
Ubrelvy	815	680	552	125
Other Eye Care	803	747	1,169	693
Ozurdex	472	428
Duodopa	468	458	511	494	461
Restasis	436	666	1,290	787
Lumigan/Ganfort	432	514	579	378
Qulipta	408	158
Other Neuroscience	276	475	685	539
Alphagan/Combigan	272	346	529	326
Epkinly	31	0
Elahere	0
Lo Loestrin				356
Lupron				752	887
Orilissa/Oriahnn				125	93
Other Women's Health				192
Synthroid				771	786
Total	54,318	58,054	56,197	45,804	33,266

Price Behavior

Price Behavior

Market Price	$228.71
Market Cap ($ Bil)	404.6
First Trading Date	01/02/2013
Distance from 52W High	-5.7%
	50 Days	200 Days
DMA Price	$227.66	$202.22
DMA Trend	up	up
Distance from DMA	0.5%	13.1%
	3M	1YR
Volatility	27.1%	26.0%
Downside Capture	10.20	20.16
Upside Capture	45.23	46.47
Correlation (SPY)	5.0%	30.4%

ABBV Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-0.24	-0.10	0.05	0.08	0.40	0.31
Up Beta	-0.68	-0.07	-0.02	0.03	0.31	0.31
Down Beta	0.43	-0.16	-0.19	-0.17	0.66	0.52
Up Capture	-25%	-12%	37%	41%	30%	7%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	10	18	31	67	130	399
Down Capture	-24%	-8%	-2%	-13%	26%	31%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	9	23	31	57	117	350

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of ABBV With Other Asset Classes (Last 1Y)
	ABBV	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	29.4%	5.8%	14.6%	57.6%	4.7%	-5.6%	-3.5%
Annualized Volatility	26.0%	17.3%	19.6%	19.4%	15.9%	17.8%	35.7%
Sharpe Ratio	0.95	0.16	0.57	2.22	0.10	-0.47	0.03
Correlation With Other Assets		67.7%	30.3%	1.0%	0.9%	49.0%	2.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of ABBV With Other Asset Classes (Last 5Y)
	ABBV	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	21.7%	8.9%	15.1%	18.0%	11.7%	4.8%	40.5%
Annualized Volatility	22.5%	14.4%	17.1%	15.5%	18.8%	19.0%	49.0%
Sharpe Ratio	0.84	0.43	0.72	0.93	0.51	0.17	0.68
Correlation With Other Assets		57.5%	27.4%	4.4%	7.2%	29.5%	3.9%

Based On 10-Year Data

		Comparison of ABBV With Other Asset Classes (Last 10Y)
	ABBV	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	19.1%	9.7%	14.5%	14.2%	5.7%	5.3%	76.1%
Annualized Volatility	26.1%	16.7%	18.0%	14.8%	17.7%	20.9%	55.9%
Sharpe Ratio	0.70	0.48	0.69	0.79	0.25	0.23	0.94
Correlation With Other Assets		63.9%	43.6%	-0.4%	14.8%	35.8%	4.5%

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	18,724,102
Short Interest: % Change Since 10312025	-0.9%
Average Daily Volume	6,259,695
Days-to-Cover Short Interest	2.99
Basic Shares Quantity	1,769,000,000
Short % of Basic Shares	1.1%

Returns Analyses

	Title
0	With AbbVie Stock Surging, Have You Considered The Downside?
1	ABBV YTD Stock Return Of 7.2% Outperforms MRK by 30% and Underperforms GILD by -12%
2	AbbVie Stock Return Comparison
3	[10/2/2021] AbbVie (ABBV) Stock Price Forecast: AI Forecasts ABBV Stock Price To Be Around $110 In A Month (Up 1.2%)
4	AbbVie Total Shareholder Return (TSR): 23.5% in 2022 and 26.9% 3-yr returns (above peer average)

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11042025	10-Q 9/30/2025
6302025	8042025	10-Q 6/30/2025
3312025	5092025	10-Q 3/31/2025
12312024	2142025	10-K 12/31/2024
9302024	11042024	10-Q 9/30/2024
6302024	8072024	10-Q 6/30/2024
3312024	5032024	10-Q 3/31/2024
12312023	2202024	10-K 12/31/2023
9302023	11062023	10-Q 9/30/2023
6302023	8072023	10-Q 6/30/2023
3312023	5052023	10-Q 3/31/2023
12312022	2172023	10-K 12/31/2022
9302022	11042022	10-Q 9/30/2022
6302022	8042022	10-Q 6/30/2022
3312022	5062022	10-Q 3/31/2022
12312021	2182022	10-K 12/31/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	8072025	Sell	198.27	3,234	641,239	13,543,427	Form
1	Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	3182025	Sell	212.34	17,644	3,746,527	2,458,260	Form
2	Buckbee Kevin K	SVP, CONTROLLER	2282025	Sell	203.40	2,684	545,926	2,572,196	Form
3	RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	2282025	Sell	202.06	1,400	282,884	10,222,417	Form
4	Siatis Perry C	EVP, GC AND SECRETARY	2242025	Sell	197.40	1,784	352,162	5,206,425	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

AbbVie (ABBV)

Market Price (12/4/2025): $230.24 | Market Cap: $407.3 BilSector: Health Care | Industry: Biotechnology

AbbVie (ABBV)

Market Price (12/4/2025): $230.24Market Cap: $407.3 BilSector: Health CareIndustry: Biotechnology

Valuation, Metrics & Events

ABBV Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About AbbVie (ABBV)

Capital Allocation Decisions (Last 3-5 Years) for AbbVie (ABBV)

Share Repurchases

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than AbbVie (ABBV)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for AbbVie

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/4/2025): $230.24 | Market Cap: $407.3 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (12/4/2025): $230.24
Market Cap: $407.3 Bil
Sector: Health Care
Industry: Biotechnology